Please try another search
For the three months ended 31 March 2022, SD Biotechnologies Co Ltd revenues decreased 33% to W24.75B. Net loss decreased 21% to W6.87B. Revenues reflect Foreign Countries segment decrease of 38% to W11.68B, South Korea (Country) segment decrease of 28% to W13.07B. Lower net loss reflects Commission Paid decrease of 44% to W3.24B (expense), R & D Expense decrease of 28% to W1.06B (expense).
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Revenue | 11813.22 | 15513.57 | 19063.18 | |
Gross Profit | 4142.82 | 2306.12 | 2221.17 | |
Operating Income | -2850.32 | -9380.62 | -9918.39 | |
Net Income | -2915.44 | -2789.92 | -9723.29 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Assets | 76122.61 | 100451.02 | 95193.4 | 99968.87 |
Total Liabilities | 31012.94 | 87635.43 | 79778.14 | 80840.23 |
Total Equity | 45109.67 | 12815.59 | 15415.26 | 19128.64 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | 7874.77 | -949.54 | -6508.47 | |
Cash From Investing Activities | -6553.35 | 974.67 | 5565.03 | |
Cash From Financing Activities | -446.61 | -478.51 | -2402.47 | |
Net Change in Cash | 602.14 | -7955.23 | 4661.42 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review